Cinzia Cavestro

Dr. Cinzia Cavestro

Headache center, Dep. Of Neurology, ASL CN2
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
PDF file
CCCinzia Cavestro
Cinzia Cavestro
ARAnnalisa Rosatello
Annalisa Rosatello
GMGianMatteo Micca
GianMatteo Micca
MRMarisa Ravotto
Marisa Ravotto
MMMaria Pia Marino
Maria Pia Marino
EBEttore Beghi
Ettore Beghi

18 August 2022 in Cells
Verified
Journal Article
Open access
PDF file
Md Asiful IslamMd Asiful Islam
Md Asiful Islam
CCCinzia Cavestro
Cinzia Cavestro
SASayeda Sadia Alam
Sayeda Sadia Alam
Shoumik KunduShoumik Kundu
Shoumik Kundu
Mohammad KamalMohammad Kamal
Mohammad Kamal
FRFaruque Reza
Faruque Reza
Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) predominantly infects the respiratory system, several investigations have shown the involvement of the central nervous system (CNS) along the course of the illness, with encephalitis being one of the symptoms. The objective of this systematic review was to evaluate the characteristics (clinical, neuro-radiological aspects, and laboratory features) and outcomes of encephalitis in COVID-19 patients. PubMed, Scopus, and Google Scholar databases were searched from 1 December 2019 until 21 July 2022 to identify case reports and case series published on COVID-19 associated with encephalitis. The quality of the included studies was assessed by the Joanna Briggs Institute critical appraisal checklists. This systematic review included 79 studies, including 91 COVID-19 patients (52.7% male) experiencing encephalitis, where 85.6% were adults (49.3 ± 20.2 years), and 14.4% were children (11.2 ± 7.6 years). RT-PCR was used to confirm 92.2% of the COVID-19 patients. Encephalitis-related symptoms were present in 78.0% of COVID-19 patients at the time of diagnosis. In these encephalitis patients, seizure (29.5%), confusion (23.2%), headache (20.5%), disorientation (15.2%), and altered mental status (11.6%) were the most frequently reported neurologic manifestations. Looking at the MRI, EEG, and CSF findings, 77.6%, 75.5%, and 64.1% of the patients represented abnormal results. SARS-CoV-2-associated or -mediated encephalitis were the most common type observed (59.3%), followed by autoimmune encephalitis (18.7%). Among the included patients, 66.7% were discharged (37.8% improved and 28.9% fully recovered), whereas 20.0% of the reported COVID-19-positive encephalitis patients died. Based on the quality assessment, 87.4% of the studies were of high quality. Although in COVID-19, encephalitis is not a typical phenomenon, SARS-CoV-2 seems like a neuropathogen affecting the brain even when there are no signs of respiratory illness, causing a high rate of disability and fatality.

15 March 2006 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
CCCinzia Cavestro
Cinzia Cavestro
ARA. Rosatello
A. Rosatello
MMM. P. Marino
M. P. Marino
GMG. Micca
G. Micca
GAG. Asteggiano
G. Asteggiano
Many factors should be considered when an episodic migraine worsens and becomes chronic. Prolactin (PRL) was linked to the origin of pain in patients with microprolactinomas who developed different types of headaches. Our team carried out studies on 27 patients with a background of episodic headaches that became chronic. The patients were evaluated by means of a general examination, a neurological examination and a hormonal profile. Of the 27 patients, 7 of them had an increased level of prolactinaemia. All the patients were women, ranging from 17 to 57 years of age. Four of them had a pure form of migraine without aura, whereas 3 patients had both migraines without aura and tension–type headaches. They suffered from headache for a period ranging from 3 to 32 years and their headache became chronic 4–12 months prior to the visit. Their headache did not change in type, but only in severity and frequency. Two patients had no symptoms referable to high PRL levels; 4 patients had irregular menses or amenorrhoea. One of these patients also suffered galactorrhoea and two of these patients had a microprolactinoma at MRI; one patient was using estroprogestinic drugs, so her menstrual alteration could not be considered. The patients were followed–up for a period of 6–16 months. Six patients responded favourably after being treated with cabergoline, although some had already tried other drugs, which, however, had no effect on their headache. One patient improved after ceasing to take estroprogestinic, in spite of increased levels of PRL. Therefore, on this basis, PRL levels should always be considered when headache worsens. It is an adjunctive worsening factor, which can be easily eliminated.

9 October 2019 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
CCCinzia Cavestro
Cinzia Cavestro
MFMarcella Ferrero
Marcella Ferrero
SMSilvia Mandrino
Silvia Mandrino
MTMarco Di Tavi
Marco Di Tavi
EREugenia Rota
Eugenia Rota
Background.: Migraine is a diffuse and disabling disease. Its pathophysiology is complex and involves both central and peripheral dysfunctions.Objective.: This review will discuss the pathogenesis of migraine from the origin of the neuro-inflammatory theory, to the modern pathophysiological model and the latest therapies.Methods.: PUBMED and EMBASE (up to May 2019) were searched for: migraine, inflammation, immunomodulation. An additional search was carried out from the bibliography of previous review articles.Results.: Migraine was thought to be mainly a vascular disorder, according to the so-called “vascular theory”. Based on animal models, a new hypothesis called “the neuro-inflammatory” was conceived at the end of the 20th century. The growing knowledge about the trigeminovascular system and its role in the inflammatory-pain pathway, allowed to identify other specific neurotransmitters, such as the Calcitonin Gene-Related Peptide and Pituitary Adenylate Cyclase-Activating Peptide. Evidence was provided that the inflammatory-pain system could become sensitised and, due to this sensitisation, the pain could also perpetuate, even in the absence of any triggers of the migraine attack. At last, brain immune cells modification during cortical spreading depression in migraine was demonstrated, along with the existence and function of the glymphatic system. The better comprehension of the immune system abnormalities allowed the development of new immunomodulating drugs: the monoclonal antibodies against the CGRP or the CGRP receptor. Moreover, new insights into the molecular mechanism of CGRP, and the function of C-fibres and Aδ-fibres, highlighted the mechanism of action of Botulinum Toxin type A in the treatment of chronic migraine.

18 May 2011 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
CCCinzia Cavestro
Cinzia Cavestro
GMG. Micca
G. Micca
FMF. Molinari
F. Molinari
MBM. Bazzan
M. Bazzan
CPC. DI Pietrantonj
C. DI Pietrantonj
DRD. Roccatello
D. Roccatello
Summary. Background: It has been observed that migraineurs show a higher risk of thrombosis and that the most frequent symptom reported by patients with antiphospholipid syndrome is headache, especially migraine. Objectives: The aim of our research was to evaluate the prevalence of antiphospholipid antibodies (aPL) in a random cohort of migraineurs. Patients/Methods: This analytic, comparative case study was performed to evaluate the prevalence of antiphospholipid antibodies by comparing a population of migraineurs with and without aura with sex‐ and age‐matched controls. Both the diagnosis of migraine and the laboratory diagnosis of aPL positivity were made on the basis of the most recent international guidelines. Results: Between September 2008 and August 2009, we recruited 284 consecutive patients (225 women and 59 men, 203 without aura and 81 with aura) and 225 controls (174 women and 51 men). Positivity for at least one test for aPL (LAC, ACA IgG or antiß2GLP1 IgG) was detected and confirmed in 12% (n = 33) of patients and in 3% (n = 7) of controls (odds ratio, 4.08; confidence interval, 1.77–9:39; P = 0.0004). Two of the patients had triple positivity for aPL (LAC, ACA and antiß2GLP1) and one had double positivity (LAC and antiß2GLP1); none of the controls showed multiple positivity. Conclusions: Our data show that migraineurs have a significantly higher prevalence of antiphospholipid antibodies, and point towards the fact that the two conditions may be comorbid or even that migraine may be an early sign for identifying patients with aPL positivity.

1 March 2018 in Journal of Medicinal Food
Verified
Journal Article
Closed access
CCCinzia Cavestro
Cinzia Cavestro
GBGiorgio Bedogni
Giorgio Bedogni
FMFilippo Molinari
Filippo Molinari
SMSilvia Mandrino
Silvia Mandrino
EREugenia Rota
Eugenia Rota
MFMaria Cristina Frigeri
Maria Cristina Frigeri
Alpha-lipoic acid (ALA) is known to lower insulin resistance (IR), which is common among migraineurs. To assess the effect of ALA on headache in migraineurs with IR, we performed an exploratory study on a cohort of patients with migraine, followed at our Headache Center. The 32 patients took ALA 400 mg b.i.d. for 6 months in addition to their on-going treatment. The percentage of patients with a reduction of at least 50% of the attacks was 0.53 (confidence interval [95% CI] 0.36–0.70) at 2 months, 0.56 (0.39–0.73) at 4 months, and 0.69 (0.53–0.85) at 6 months. The incidence rate ratio of attacks at 6 months versus baseline was 0.48 (0.43–0.53, P < .001), corresponding to a mean (95% CI) number of attacks of 5 (4–6) versus 11 (10–12). The number of days of treatment in the previous month was 7.7 (6.8–8.7) at baseline, 5.4 (4.6–6.2) at 2 months, 5.3 (4.5–6.1) at 4 months, and 4.3 (3.6–5.0) at 6 months. Baseline and 120-min glucose and insulin and quantitative insulin sensitivity check index (QUICKI) and the Stumvoll index did not change at 6 months versus baseline. This exploratory study shows that the administration of ALA may be associated with a reduction in the number of attacks and the days of treatment in migraineurs with IR. A randomized controlled trial is needed to test this possibility.